Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells

25 Apr 2012

Abstract excerpt

Pharmacological activation of wild-type p53 has been found to protect normal cells in culture from cytotoxicity and nuclear aberrations caused by conventional cancer therapeutics. Hence, small-molecule p53 activators could have clinical benefits as chemoprotectants for cancer patients bearing p53-mutant tumors. We have evaluated 16 p53-based cyclotherapy regimes combining p53 activators tenovin-6, leptomycin B,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cancer Research and Treatments
Share to DNA Repair Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22517433
DOI: 10.4161/cc.20254

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cellsPMID 22517433Read ↗

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy.Semantic proximity Read ↗

p53-Based cyclotherapy: exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapySemantic proximity Read ↗

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapySemantic proximity Read ↗

Small molecule compounds targeting the p53 pathway: are we finally making progress?Semantic proximity Read ↗

P53: an ubiquitous target of anticancer drugs.Semantic proximity Read ↗

The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and PromiseSemantic proximity Read ↗

Pharmacological activation of p53 in cancer cells.Semantic proximity Read ↗

A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53Semantic proximity Read ↗

A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53.Semantic proximity Read ↗

An evaluation of the ability of pifithrin-α and -β to inhibit p53 function in two wild-type p53 human tumor cell linesSemantic proximity Read ↗

RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.Semantic proximity Read ↗

Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic AgentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.